JP2019535791A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535791A5 JP2019535791A5 JP2019528540A JP2019528540A JP2019535791A5 JP 2019535791 A5 JP2019535791 A5 JP 2019535791A5 JP 2019528540 A JP2019528540 A JP 2019528540A JP 2019528540 A JP2019528540 A JP 2019528540A JP 2019535791 A5 JP2019535791 A5 JP 2019535791A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- subject
- risk
- reduce
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 10
- 208000013016 Hypoglycemia Diseases 0.000 claims 5
- 108090001061 Insulin Proteins 0.000 claims 5
- 102000004877 Insulin Human genes 0.000 claims 5
- 230000002218 hypoglycaemic effect Effects 0.000 claims 5
- 229940125396 insulin Drugs 0.000 claims 5
- 229960004225 insulin degludec Drugs 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 claims 4
- 108010050259 insulin degludec Proteins 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 230000002411 adverse Effects 0.000 claims 2
- 230000007211 cardiovascular event Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000002641 glycemic effect Effects 0.000 claims 2
- 239000005022 packaging material Substances 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 1
- 206010027525 Microalbuminuria Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 210000003423 ankle Anatomy 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 1
- 238000011866 long-term treatment Methods 0.000 claims 1
- 239000003538 oral antidiabetic agent Substances 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16200993.0 | 2016-11-28 | ||
| EP16200993 | 2016-11-28 | ||
| EP17162803 | 2017-03-24 | ||
| EP17162803.5 | 2017-03-24 | ||
| EP17174687 | 2017-06-07 | ||
| EP17174687.8 | 2017-06-07 | ||
| PCT/EP2017/080603 WO2018096163A1 (en) | 2016-11-28 | 2017-11-28 | Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019535791A JP2019535791A (ja) | 2019-12-12 |
| JP2019535791A5 true JP2019535791A5 (enExample) | 2020-12-17 |
Family
ID=60702634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528540A Withdrawn JP2019535791A (ja) | 2016-11-28 | 2017-11-28 | 血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11673933B2 (enExample) |
| EP (1) | EP3544682A1 (enExample) |
| JP (1) | JP2019535791A (enExample) |
| CN (1) | CN110099719A (enExample) |
| MA (1) | MA46890A (enExample) |
| WO (1) | WO2018096163A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11278596B2 (en) | 2016-11-28 | 2022-03-22 | Novo Nordisk A/S | Insulin degludec in cardiovascular conditions |
| US11673933B2 (en) | 2016-11-28 | 2023-06-13 | Novo Nordisk A/S | Method for using insulin degludec for the improvement of glycemic control and reduction of acute and long-term diabetes complications |
| AR112015A1 (es) | 2017-06-09 | 2019-09-11 | Novo Nordisk As | Composiciones sólidas para administración oral |
| US20230158234A1 (en) * | 2021-11-22 | 2023-05-25 | Colleen Cook | Method of Insulin Administration |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ300837B6 (cs) | 1996-08-30 | 2009-08-26 | Novo Nordisk A/S | Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití |
| GB0309154D0 (en) | 2003-01-14 | 2003-05-28 | Aventis Pharma Inc | Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia |
| JP4463814B2 (ja) | 2003-08-05 | 2010-05-19 | ノボ ノルディスク アクティーゼルスカブ | 新規のインスリン誘導体 |
| RU2014143271A (ru) | 2012-03-28 | 2016-05-20 | Санофи | Базовая инсулинотерапия |
| JP6755175B2 (ja) * | 2013-03-20 | 2020-09-16 | ノヴォ ノルディスク アー／エス | インスリン投薬レジメン |
| JP2016519127A (ja) * | 2013-04-30 | 2016-06-30 | ノヴォ ノルディスク アー／エス | 新規投与レジメン |
| US11673933B2 (en) | 2016-11-28 | 2023-06-13 | Novo Nordisk A/S | Method for using insulin degludec for the improvement of glycemic control and reduction of acute and long-term diabetes complications |
-
2017
- 2017-11-28 US US16/463,594 patent/US11673933B2/en active Active
- 2017-11-28 WO PCT/EP2017/080603 patent/WO2018096163A1/en not_active Ceased
- 2017-11-28 CN CN201780073532.XA patent/CN110099719A/zh not_active Withdrawn
- 2017-11-28 JP JP2019528540A patent/JP2019535791A/ja not_active Withdrawn
- 2017-11-28 EP EP17816532.0A patent/EP3544682A1/en not_active Withdrawn
- 2017-11-28 MA MA046890A patent/MA46890A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Deacon | A review of dipeptidyl peptidase‐4 inhibitors. Hot topics from randomized controlled trials | |
| Raz | Guideline approach to therapy in patients with newly diagnosed type 2 diabetes | |
| Aryangat et al. | Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk | |
| Wysham et al. | Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial | |
| Retnakaran et al. | Short‐term intensified insulin treatment in type 2 diabetes: long‐term effects on β‐cell function | |
| JP2019535791A5 (enExample) | ||
| Carbone et al. | Glucose-lowering therapies for cardiovascular risk reduction in type 2 diabetes mellitus: state-of-the-art review | |
| Hanefeld | Use of insulin in type 2 diabetes: what we learned from recent clinical trials on the benefits of early insulin initiation | |
| EA201590759A1 (ru) | Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина | |
| HRP20221368T1 (hr) | Terapijske uporabe empagliflozina | |
| JP2020502151A5 (enExample) | ||
| JP2019535785A5 (enExample) | ||
| Chan et al. | Glycaemic responses in Asian and non-Asian people with type 2 diabetes initiating insulin glargine 100 units/mL: a patient-level pooled analysis of 16 randomised controlled trials | |
| Ji | Treatment strategy for type 2 diabetes with obesity: focus on glucagon-like peptide-1 receptor agonists | |
| Napoli et al. | Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society | |
| BR112021017315A2 (pt) | Usos terapêuticos de dulaglutida | |
| Newlin Lew | Pharmacotherapy of Type 2 Diabetes Mellitus: Navigating Current and New Therapies. | |
| Gallwitz | The future of combination therapies of insulin with a glucagon-like peptide-1 receptor agonists in type 2 diabetes–Is it advantageous? | |
| FORCE | AACE/ACE Comprehensive Diabetes Management Algorithm | |
| Buturovic et al. | Effects of teraphy with basal insulin analogues combined with GLP 1 analogues and metformin in the treatment of obese patients with poorly regulated postprandial glycemia | |
| Eriksson et al. | Second-line treatment with sulfonylurea compared to DPP4 inhibitors is associated with risk of cardiovascular disease, all-cause mortality and severe hypoglycaemia | |
| Schwarz | Inflammation as a factor of the pathogenesis of insulin resistance and type 2 diabetes | |
| Lau | Canada welcomes a novel class of oral glucose-lowering drugs for people with type 2 diabetes | |
| Khamseh et al. | Metabolic control and prevalence of diabetes related complications in patients with type 2 diabetes: baseline results of the A1chieve study | |
| YALE et al. | Canagliflozin demonstrates durable glycemic improvements over 104 weeks compared with glimepiride in subjects with type 2 diabetes mellitus on metformin |